Compendia Bioscience Signs Oncomine Licensing Agreement with AstraZeneca
ANN ARBOR, Mich., December 04, 2007 /PRNewswire/ -- Compendia Bioscience, Inc. today announced that it has licensed Oncomine(TM) - the company's compendium of oncology gene expression profiles and analysis tools - to AstraZeneca, which will conduct a yearlong pilot to evaluate the long-term role of this product in its cancer research programs.
This licensing agreement gives AstraZeneca access to Oncomine(TM) Concepts Edition (OCM), a value-added product extension of Oncomine that combines nearly 7,000 proprietary cancer gene signatures with 11,000 gene, protein, drug, and pathway signatures collected from the literature and other public sources. The Concepts Map application uses gene sets as a common language to compare and link disparate biological concepts, allowing researchers to discover and explore new biology based on signatures related to drugs and/or disease pathways.
"We are pleased to welcome AstraZeneca to our growing list of major pharmaceutical and biotech customers," said John Freshley, Chief Business Officer of Compendia Bioscience. "We have an excellent track record of success with this group of companies and are confident AstraZeneca's experience will be similar."
"We are optimistic about Oncomine's potential impact on our oncology research programs," said Jeff Hanke, Vice President, Cancer Discovery, AstraZeneca. "The novel Concepts Map application may allow us to leverage traditional gene expression data in innovative new ways."
A recent study published in Nature Genetics (2007 Jan; 39(1): 41-51) used Oncomine Concepts Map to analyze prostate cancer gene expression in the context of the other gene signatures available in OCM. The result was an important new model describing the progression of prostate cancer.
Oncomine Concepts Map is licensed to commercial users as part of the Oncomine Concepts Edition and the Oncomine Enterprise Edition.
About Compendia Bioscience, Inc.
Compendia Bioscience is dedicated to harnessing the global collection of high throughput molecular data to provide researchers with the data and analysis tools necessary to validate biomarker and gene target discoveries, better understand mechanisms of disease, and optimize clinical outcomes.
About Oncomine(TM)
Oncomine(TM) combines a rapidly growing compendium of 20,000+ cancer transcriptome profiles with a sophisticated analysis engine and a powerful web application for data mining and visualization. Oncomine facilitates rapid and reliable biomarker and therapeutic target discovery, validation, and prioritization.
CONTACT: Jane Krug of Compendia Bioscience, Inc., +1-410-889-1971, media@compendiabio.com
Web site: http://www.compendiabio.com/
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights
reserved.
A United Business Media Company
Pharma Industry News Archive
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec
